Clincosm LogoSign in Get a demo

NEKO: Neuromuscular Control in Knee Osteoarthritis

Sponsor
Martijn Steultjens (Other)
Overall Status
Completed
CT.gov ID
NCT02314715
Collaborator
(none)
95
Enrollment
1
Location
15
Duration (Months)
6.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Arthritis is one of the most prevailing causes of disability with knee osteoarthritis (KOA) the most common form. The lifetime risk of developing symptomatic KOA by the age of 85 years is 44.7%, where females are at a greater risk (1.8 times) than male counter parts. KOA is the leading cause of limitations in activities of daily living such as walking and climbing stairs particularly in the elderly. This is primarily due to pain and instability of the joint resulting in buckling of knees caused by muscle weakness, joint stiffness and damage. Patients with KOA have larger variations in muscle strength and are unable to maintain a target force combined with impaired ability to perceive joint movement and positioning suggests impaired neuromuscular control (NC) may influence KOA. NC refers to the nervous system's control over muscle activation contributing to task performance. This study aims to establish the role of loss of NC in biomechanical determinants and health outcomes of KOA.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    95 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Neuromuscular Control in Knee Osteoarthritis
    Study Start Date :
    Nov 1, 2013
    Actual Primary Completion Date :
    Feb 1, 2015
    Actual Study Completion Date :
    Feb 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    Knee Osteoarthritis

    Participants with diagnosed knee osteoarthritis
    Controls

    Participants without knee osteoarthritis

    Outcome Measures

    Primary Outcome Measures

    1. Neuromuscular Control [1 day]

      Neuromuscular control will be assessed through muscle co-activation index from electromyography (EMG) of the hamstrings, quadriceps and gastrocnemius. The electromechanical delay (delay between the onset of EMG and force), active proprioception and force accuracy and steadiness measure determined from submaximal isometric contractions will be used to determine neuromuscular control

    Secondary Outcome Measures

    1. Disease Outcome [1 day]

      Joint damage scored using the Boston Leeds Osteoarthritis Knee Score (BLOKS) from 1.5T MRI along with pain and function assessed from knee injury and osteoarthritis score (KOOS) and patient reported outcomes measurement information system (PROMIS) will be used to determine disease outcome.

    Other Outcome Measures

    1. Determinants of knee osteoarthritis [1 day]

      Muscle strength (peak force) will be assessed from maximal isometric contractions of the knee, along with passive motion and position sense proprioception as determinants of knee osteoarthritis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Knee osteoarthritis participants only:

    • Knee Osteoarthritis confirmed by a physician using the American College of Rheumatology (ACR 1986) Criteria

    • Have unilateral or bilateral knee osteoarthritis

    • Aged 40 years or over.

    Healthy control participants only:

    • Have no history of unilateral/bilateral knee osteoarthritis

    • Had no current chronic/stable knee pain in the past 3 months

    • Aged 40 years or over.

    Exclusion Criteria:
    All participants are excluded if they:

    • Have neuromuscular skeletal injury/illness (e.g.Multiple Sclerosis, Parkinson's disease, Muscular Dystrophy, Cerebral Palsy)

    • Have had knee surgery, knee arthroplastic surgery and arthroscopic debridement or corrective surgery for knee osteoarthritis in the past 12 months

    • Have had corticosteroid injections to or around the knee in the past 3 months.

    • Have unstable heart disease

    • Previously had a stroke

    • Have insulin-dependent diabetes

    • Have osteoporosis

    • Have a history of falls and other motor deficits

    • Are unable to walk up and down stairs

    • Are unable to rise from a chair without the aid of another person

    • Have an unstable medication schedule and medication that causes dizziness

    • Have Dementia/Alzheimer's/ an inability to comprehend, follow instructions and give informed consent

    • Have an inability to lie flat for 60 minutes Have mental in their body.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Glasgow Caledonian University Glasgow United Kingdom G4 0BA

    Sponsors and Collaborators

    • Martijn Steultjens

    Investigators

    • Principal Investigator: Stephanie L Smith, MRes, Glasgow Caledonian University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Martijn Steultjens, Professor of Musculoskeletal Health, Glasgow Caledonian University
    ClinicalTrials.gov Identifier:
    NCT02314715
    Other Study ID Numbers:
    • GCU_MSK_SS_001
    First Posted:
    Dec 11, 2014
    Last Update Posted:
    Mar 3, 2015
    Last Verified:
    Mar 1, 2015
    Keywords provided by Martijn Steultjens, Professor of Musculoskeletal Health, Glasgow Caledonian University
    Osteoarthritis Knee
    Additional relevant MeSH terms:
    Osteoarthritis
    Osteoarthritis, Knee

    Study Results

    No Results Posted as of Mar 3, 2015